tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Poseida Therapeutics says FDA grants RMAT designation to P-BCMA-ALLO1

Poseida Therapeutics announced that the U.S. FDA granted Regenerative Medicine Advanced Therapy designation to P-BCMA-ALLO1, an investigational stem cell memory T cell-based allogeneic CAR-T cell therapy in Phase 1/1b clinical development for the treatment of patients with relapsed/refractory multiple myeloma.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1